# Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

> **NCT00070252** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 53 (actual)

## Conditions studied

- Adult Solid Neoplasm
- Inflammatory Breast Carcinoma
- Male Breast Carcinoma
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Docetaxel
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Tipifarnib

## Key facts

- **NCT ID:** NCT00070252
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2006-02
- **Final completion:** 2010-06
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2015-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00070252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00070252, "Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00070252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*